Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: a matter of undetermined significance
Plasma cell myeloma, characterized by clonally aberrant plasma cells that produce abnormal monoclonal Igs, is the most common indication for autologous hematopoietic progenitor cell transplantation (AHPCT) in North America. We observed appearance of new monoclonal gammopathies different from the ori...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2012-09, Vol.47 (9), p.1212-1216 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1216 |
|---|---|
| container_issue | 9 |
| container_start_page | 1212 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 47 |
| creator | Manson, G V Campagnaro, E Balog, A Kaplan, D Sommers, S R Fu, P Rajkumar, S V Lazarus, H M |
| description | Plasma cell myeloma, characterized by clonally aberrant plasma cells that produce abnormal monoclonal Igs, is the most common indication for autologous hematopoietic progenitor cell transplantation (AHPCT) in North America. We observed appearance of new monoclonal gammopathies different from the original protein in the post-AHPCT setting and termed this condition ‘secondary MGUS’ (monoclonal gammopathy of undetermined significance). Hence, we performed a retrospective, single institution review of serum protein electrophoresis/immunofixation electrophoresis data in 92 AHPCT recipients from the period 2000–2009. In all, 22 of 92 patients (24%) undergoing AHPCT met criteria for secondary MGUS. Contrary to previous studies, often referred to as ‘abnormal protein banding,’ we did not observe this condition as a favorable prognostic indicator in affected patients when compared with the control group (
P
=0.686). However, we did note that a subgroup of the study cohort who developed secondary MGUS after a prolonged latency (>10 months) had an improved median OS compared with the remainder of the study cohort (75 months vs 41 months,
P
=0.005). As there have been significant advancements in understanding the pathobiology and clinical significance of MGUS, we believe that secondary MGUS merits dedication of resources for investigation to determine its true clinical relevance, prognostic value and pathophysiology. |
| doi_str_mv | 10.1038/bmt.2011.244 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1069199736</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A302463117</galeid><sourcerecordid>A302463117</sourcerecordid><originalsourceid>FETCH-LOGICAL-c584t-e75a13185e73ec26122fc1b0b874550bdabd3d682ca9b323b665ca22d903c1713</originalsourceid><addsrcrecordid>eNqNkktv1DAUhS0EomVgxxpZQiAWZPAjdhx2VQUFqYhF6TpynJsZV4k9xM6iv4E_zQ0z0BZVCHnh13ePfexDyHPO1pxJ864d81owzteiLB-QY15WulBSq4fkmAltCil1fUSepHTFGC9Lph6TIyG4MtJUx-THBbgYOjtd0y9nlxfU9hkmaucch7iJc6JbGG2Ou-ghe0d3U9xA8DlO1MEw0DzZkHaDDdlmHwP1geIsjXa_PV7DEEf7nlqKKoty7OkcOsDh6AN0NPlN8L13Njh4Sh71dkjw7NCvyOXHD99OPxXnX88-n56cF06ZMhdQKcslNwoqCU5oLkTveMtaU5VKsbazbSc7bYSzdSuFbLVWzgrR1Uw6XnG5Im_2uujm-wwpN6NPy31tALTccKZrXteV1P-BSiOEMii9Ii__Qq_iPAU00ghdIiRrZv5FoVZVC1EyfUNt7ACND33Eh3bL0c2JZKLUkvMKqfU9FLYORo-_Cr3H9TsFr28VbMEOeZviMC9fl-6Cb_egm2JKE_TNbvIjhgQv-ctzg6lrltQ1mDrEXxxMze0I3R_4d8wQeHUAbHJ26DE1zqcbTkvFlV6Eij2XcCtsYLr9Ovcc_BPt3-wt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1037922406</pqid></control><display><type>article</type><title>Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: a matter of undetermined significance</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Manson, G V ; Campagnaro, E ; Balog, A ; Kaplan, D ; Sommers, S R ; Fu, P ; Rajkumar, S V ; Lazarus, H M</creator><creatorcontrib>Manson, G V ; Campagnaro, E ; Balog, A ; Kaplan, D ; Sommers, S R ; Fu, P ; Rajkumar, S V ; Lazarus, H M</creatorcontrib><description>Plasma cell myeloma, characterized by clonally aberrant plasma cells that produce abnormal monoclonal Igs, is the most common indication for autologous hematopoietic progenitor cell transplantation (AHPCT) in North America. We observed appearance of new monoclonal gammopathies different from the original protein in the post-AHPCT setting and termed this condition ‘secondary MGUS’ (monoclonal gammopathy of undetermined significance). Hence, we performed a retrospective, single institution review of serum protein electrophoresis/immunofixation electrophoresis data in 92 AHPCT recipients from the period 2000–2009. In all, 22 of 92 patients (24%) undergoing AHPCT met criteria for secondary MGUS. Contrary to previous studies, often referred to as ‘abnormal protein banding,’ we did not observe this condition as a favorable prognostic indicator in affected patients when compared with the control group (
P
=0.686). However, we did note that a subgroup of the study cohort who developed secondary MGUS after a prolonged latency (>10 months) had an improved median OS compared with the remainder of the study cohort (75 months vs 41 months,
P
=0.005). As there have been significant advancements in understanding the pathobiology and clinical significance of MGUS, we believe that secondary MGUS merits dedication of resources for investigation to determine its true clinical relevance, prognostic value and pathophysiology.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/bmt.2011.244</identifier><identifier>PMID: 22158387</identifier><identifier>CODEN: BMTRE9</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/249/1573 ; 692/699/67/1990/804 ; 692/700/565/545/576/1855 ; Adult ; Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Autografts ; Benign monoclonal gammopathy ; Biological and medical sciences ; Bone marrow ; Bone marrow transplantation ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Care and treatment ; Cell Biology ; Cells (biology) ; Data processing ; Diagnosis ; Electrophoresis ; Female ; Hematologic and hematopoietic diseases ; Hematology ; Hematopoietic Stem Cell Transplantation - adverse effects ; Hematopoietic Stem Cell Transplantation - methods ; Hematopoietic stem cells ; Hemopoiesis ; Humans ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulinopathies ; Immunopathology ; Internal Medicine ; Latency ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Monoclonal gammopathies ; Monoclonal gammopathy ; Monoclonal Gammopathy of Undetermined Significance - etiology ; Multiple myeloma ; Multiple Myeloma - blood ; Multiple Myeloma - surgery ; Myeloma ; original-article ; Patients ; Plasma cells ; Progenitor cells ; Proteins ; Public Health ; Retrospective Studies ; Serum proteins ; Stem cell transplantation ; Stem Cells ; Subgroups ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation ; Transplantation, Autologous</subject><ispartof>Bone marrow transplantation (Basingstoke), 2012-09, Vol.47 (9), p.1212-1216</ispartof><rights>Macmillan Publishers Limited 2012</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2012 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Sep 2012</rights><rights>Macmillan Publishers Limited 2012.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c584t-e75a13185e73ec26122fc1b0b874550bdabd3d682ca9b323b665ca22d903c1713</citedby><cites>FETCH-LOGICAL-c584t-e75a13185e73ec26122fc1b0b874550bdabd3d682ca9b323b665ca22d903c1713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/bmt.2011.244$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/bmt.2011.244$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26351564$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22158387$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Manson, G V</creatorcontrib><creatorcontrib>Campagnaro, E</creatorcontrib><creatorcontrib>Balog, A</creatorcontrib><creatorcontrib>Kaplan, D</creatorcontrib><creatorcontrib>Sommers, S R</creatorcontrib><creatorcontrib>Fu, P</creatorcontrib><creatorcontrib>Rajkumar, S V</creatorcontrib><creatorcontrib>Lazarus, H M</creatorcontrib><title>Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: a matter of undetermined significance</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>Plasma cell myeloma, characterized by clonally aberrant plasma cells that produce abnormal monoclonal Igs, is the most common indication for autologous hematopoietic progenitor cell transplantation (AHPCT) in North America. We observed appearance of new monoclonal gammopathies different from the original protein in the post-AHPCT setting and termed this condition ‘secondary MGUS’ (monoclonal gammopathy of undetermined significance). Hence, we performed a retrospective, single institution review of serum protein electrophoresis/immunofixation electrophoresis data in 92 AHPCT recipients from the period 2000–2009. In all, 22 of 92 patients (24%) undergoing AHPCT met criteria for secondary MGUS. Contrary to previous studies, often referred to as ‘abnormal protein banding,’ we did not observe this condition as a favorable prognostic indicator in affected patients when compared with the control group (
P
=0.686). However, we did note that a subgroup of the study cohort who developed secondary MGUS after a prolonged latency (>10 months) had an improved median OS compared with the remainder of the study cohort (75 months vs 41 months,
P
=0.005). As there have been significant advancements in understanding the pathobiology and clinical significance of MGUS, we believe that secondary MGUS merits dedication of resources for investigation to determine its true clinical relevance, prognostic value and pathophysiology.</description><subject>692/699/249/1573</subject><subject>692/699/67/1990/804</subject><subject>692/700/565/545/576/1855</subject><subject>Adult</subject><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Autografts</subject><subject>Benign monoclonal gammopathy</subject><subject>Biological and medical sciences</subject><subject>Bone marrow</subject><subject>Bone marrow transplantation</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Care and treatment</subject><subject>Cell Biology</subject><subject>Cells (biology)</subject><subject>Data processing</subject><subject>Diagnosis</subject><subject>Electrophoresis</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hematopoietic stem cells</subject><subject>Hemopoiesis</subject><subject>Humans</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Internal Medicine</subject><subject>Latency</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Monoclonal gammopathies</subject><subject>Monoclonal gammopathy</subject><subject>Monoclonal Gammopathy of Undetermined Significance - etiology</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - blood</subject><subject>Multiple Myeloma - surgery</subject><subject>Myeloma</subject><subject>original-article</subject><subject>Patients</subject><subject>Plasma cells</subject><subject>Progenitor cells</subject><subject>Proteins</subject><subject>Public Health</subject><subject>Retrospective Studies</subject><subject>Serum proteins</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Subgroups</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation</subject><subject>Transplantation, Autologous</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkktv1DAUhS0EomVgxxpZQiAWZPAjdhx2VQUFqYhF6TpynJsZV4k9xM6iv4E_zQ0z0BZVCHnh13ePfexDyHPO1pxJ864d81owzteiLB-QY15WulBSq4fkmAltCil1fUSepHTFGC9Lph6TIyG4MtJUx-THBbgYOjtd0y9nlxfU9hkmaucch7iJc6JbGG2Ou-ghe0d3U9xA8DlO1MEw0DzZkHaDDdlmHwP1geIsjXa_PV7DEEf7nlqKKoty7OkcOsDh6AN0NPlN8L13Njh4Sh71dkjw7NCvyOXHD99OPxXnX88-n56cF06ZMhdQKcslNwoqCU5oLkTveMtaU5VKsbazbSc7bYSzdSuFbLVWzgrR1Uw6XnG5Im_2uujm-wwpN6NPy31tALTccKZrXteV1P-BSiOEMii9Ii__Qq_iPAU00ghdIiRrZv5FoVZVC1EyfUNt7ACND33Eh3bL0c2JZKLUkvMKqfU9FLYORo-_Cr3H9TsFr28VbMEOeZviMC9fl-6Cb_egm2JKE_TNbvIjhgQv-ctzg6lrltQ1mDrEXxxMze0I3R_4d8wQeHUAbHJ26DE1zqcbTkvFlV6Eij2XcCtsYLr9Ovcc_BPt3-wt</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>Manson, G V</creator><creator>Campagnaro, E</creator><creator>Balog, A</creator><creator>Kaplan, D</creator><creator>Sommers, S R</creator><creator>Fu, P</creator><creator>Rajkumar, S V</creator><creator>Lazarus, H M</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20120901</creationdate><title>Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: a matter of undetermined significance</title><author>Manson, G V ; Campagnaro, E ; Balog, A ; Kaplan, D ; Sommers, S R ; Fu, P ; Rajkumar, S V ; Lazarus, H M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c584t-e75a13185e73ec26122fc1b0b874550bdabd3d682ca9b323b665ca22d903c1713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>692/699/249/1573</topic><topic>692/699/67/1990/804</topic><topic>692/700/565/545/576/1855</topic><topic>Adult</topic><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Autografts</topic><topic>Benign monoclonal gammopathy</topic><topic>Biological and medical sciences</topic><topic>Bone marrow</topic><topic>Bone marrow transplantation</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Care and treatment</topic><topic>Cell Biology</topic><topic>Cells (biology)</topic><topic>Data processing</topic><topic>Diagnosis</topic><topic>Electrophoresis</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hematopoietic stem cells</topic><topic>Hemopoiesis</topic><topic>Humans</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Internal Medicine</topic><topic>Latency</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Monoclonal gammopathies</topic><topic>Monoclonal gammopathy</topic><topic>Monoclonal Gammopathy of Undetermined Significance - etiology</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - blood</topic><topic>Multiple Myeloma - surgery</topic><topic>Myeloma</topic><topic>original-article</topic><topic>Patients</topic><topic>Plasma cells</topic><topic>Progenitor cells</topic><topic>Proteins</topic><topic>Public Health</topic><topic>Retrospective Studies</topic><topic>Serum proteins</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Subgroups</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation</topic><topic>Transplantation, Autologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Manson, G V</creatorcontrib><creatorcontrib>Campagnaro, E</creatorcontrib><creatorcontrib>Balog, A</creatorcontrib><creatorcontrib>Kaplan, D</creatorcontrib><creatorcontrib>Sommers, S R</creatorcontrib><creatorcontrib>Fu, P</creatorcontrib><creatorcontrib>Rajkumar, S V</creatorcontrib><creatorcontrib>Lazarus, H M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Manson, G V</au><au>Campagnaro, E</au><au>Balog, A</au><au>Kaplan, D</au><au>Sommers, S R</au><au>Fu, P</au><au>Rajkumar, S V</au><au>Lazarus, H M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: a matter of undetermined significance</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2012-09-01</date><risdate>2012</risdate><volume>47</volume><issue>9</issue><spage>1212</spage><epage>1216</epage><pages>1212-1216</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><coden>BMTRE9</coden><abstract>Plasma cell myeloma, characterized by clonally aberrant plasma cells that produce abnormal monoclonal Igs, is the most common indication for autologous hematopoietic progenitor cell transplantation (AHPCT) in North America. We observed appearance of new monoclonal gammopathies different from the original protein in the post-AHPCT setting and termed this condition ‘secondary MGUS’ (monoclonal gammopathy of undetermined significance). Hence, we performed a retrospective, single institution review of serum protein electrophoresis/immunofixation electrophoresis data in 92 AHPCT recipients from the period 2000–2009. In all, 22 of 92 patients (24%) undergoing AHPCT met criteria for secondary MGUS. Contrary to previous studies, often referred to as ‘abnormal protein banding,’ we did not observe this condition as a favorable prognostic indicator in affected patients when compared with the control group (
P
=0.686). However, we did note that a subgroup of the study cohort who developed secondary MGUS after a prolonged latency (>10 months) had an improved median OS compared with the remainder of the study cohort (75 months vs 41 months,
P
=0.005). As there have been significant advancements in understanding the pathobiology and clinical significance of MGUS, we believe that secondary MGUS merits dedication of resources for investigation to determine its true clinical relevance, prognostic value and pathophysiology.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>22158387</pmid><doi>10.1038/bmt.2011.244</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2012-09, Vol.47 (9), p.1212-1216 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1069199736 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | 692/699/249/1573 692/699/67/1990/804 692/700/565/545/576/1855 Adult Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Autografts Benign monoclonal gammopathy Biological and medical sciences Bone marrow Bone marrow transplantation Bone marrow, stem cells transplantation. Graft versus host reaction Care and treatment Cell Biology Cells (biology) Data processing Diagnosis Electrophoresis Female Hematologic and hematopoietic diseases Hematology Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - methods Hematopoietic stem cells Hemopoiesis Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Internal Medicine Latency Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Medicine Medicine & Public Health Middle Aged Monoclonal gammopathies Monoclonal gammopathy Monoclonal Gammopathy of Undetermined Significance - etiology Multiple myeloma Multiple Myeloma - blood Multiple Myeloma - surgery Myeloma original-article Patients Plasma cells Progenitor cells Proteins Public Health Retrospective Studies Serum proteins Stem cell transplantation Stem Cells Subgroups Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Transplantation, Autologous |
| title | Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: a matter of undetermined significance |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T15%3A52%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Secondary%20MGUS%20after%20autologous%20hematopoietic%20progenitor%20cell%20transplantation%20in%20plasma%20cell%20myeloma:%20a%20matter%20of%20undetermined%20significance&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Manson,%20G%20V&rft.date=2012-09-01&rft.volume=47&rft.issue=9&rft.spage=1212&rft.epage=1216&rft.pages=1212-1216&rft.issn=0268-3369&rft.eissn=1476-5365&rft.coden=BMTRE9&rft_id=info:doi/10.1038/bmt.2011.244&rft_dat=%3Cgale_proqu%3EA302463117%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1037922406&rft_id=info:pmid/22158387&rft_galeid=A302463117&rfr_iscdi=true |